Short answer
Penumbra Inc (PEN) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results released October 29, 2026, covering quarter ended September 30, 2026.
Penumbra Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results released October 29, 2026, covering quarter ended September 30, 2026
- Financial figures and management commentary contained in Exhibit 99.1, the accompanying earnings release
- Results furnished under Regulation FD, not filed under Exchange Act Section 18 liability provisions
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $410.1M, up 15.6%, led by thrombectomy growth of 18.1% to $279.2M
- U.S. revenue growth 17.9% outpaced international growth 7.8%, highlighting domestic concentration
- Gross margin 68.3%, up 0.5%, but operating expenses rose to $229.6M, including $7.1M acquisition costs
- Net income fell to $42.3M from $45.9M as income taxes increased to $14.0M from $6.5M
- No 2026 guidance or earnings call due to pending Boston Scientific acquisition, increasing transaction-dependency for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Penumbra Inc 8-K filings
Get the next PEN 8-K as it lands
Follow PEN for push alerts, or ask the research agent what this filing means.